buying 2007 microsoft office suite nero 9 reloaded best price dragon naturally speaking cheapest cheap windows xp 32 buy wordperfect office x4 standard buy autodesk revit 2010 cheap adobe premiere cs4 price of adobe photoshop cs4 cheap norton ghost 9.0 buy autocad 2005 autodesk revit lt 2015 prices cheap roxio creator 2010 pro buy sage act software buy flash 8 online cheap windows xp home upgrade cheap microsoft office 2010 home and business buy office 2010 home and student best buy buying filemaker pro 10 best price microsoft office for mac mindjet discount code cheap adobe creative suite 4 best buy nero 9 reloaded cheap windows 7 full version price of eset smart security download acdsee 10 license code buy corel wordperfect 10 cheap office 2010 pro buy cs5 design standard buy autocad 2010 uk buying outlook express email

Glowing Cornell Dots Target Cancer

Wed, Jun 15, 2011

Oral Cancer News

SOURCE: Journal of Clinical Investigation, June 13, 2011

(Ivanhoe Newswire)– New medical technology is showing that Cornell dots may be a potential cancer diagnostic tool. The U.S Food and Drug Administration (FDA) has recently approved the first clinical trial in humans using Cornell Dots- brightly glowing nanoparticles that can light up cancer cells in PET-optical imaging.

Cornell Dots are silica spheres less than eight nanometers in diameter that enclose several dye molecules. To make the dots stick to tumor cells, organic molecules that bind to tumor surfaces, or even specific locations within the tumors, can be attached to a polyethylene glycol shell. This shell, also referred to as PEG, prevents the body from recognizing the dots as foreign substances. When exposed to near-infrared light, the dots fluoresce much brighter than dye to serve as a beacon identifying the target cells. Researchers say this technology enables visualization during surgical treatment.

Cornell Dots were first developed in 2005 by Hooisweng Ow, a coauthor of the paper on this study and once a graduate student working with Ulrich Wiesner, Cornell Professor of Materials Science and Engineering. Ow and other researchers of this technology are currently in the process of forming a new commercial entity in New York City that will help transition this research into commercial products that will benefit cancer patients.

Michelle S. Bradbury, M.D, of the Memorial Sloan-Kettering Cancer Center and an assistant professor of radiology at Weill Cornell Medical College, was quoted as saying, “This is the first FDA IND approved inorganic particle platform of its class and properties that can be used for multiple clinical indications as well as cancer disease staging and tumor burden assessment via lymph node mapping.”

Scientists are able to perform real-time imaging of lymphatic drainage patterns and particle clearance rates as well as sensitivity, to detect nodal metastases. Nodal mapping is also being pursued which is expected to lead to another clinical trial in humans.

This news story was resourced by the Oral Cancer Foundation, and vetted for appropriateness and accuracy.

 

Print Friendly
Be Sociable, Share!
, , , , , , ,

Leave a Reply

You must be logged in to post a comment.